S. Giacchetti, G. Bjarnason, C. Garufi, D. Genet, and S. Iacobelli, Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group, Journal of Clinical Oncology, vol.24, issue.22, pp.3562-3571, 2006.
DOI : 10.1200/JCO.2006.06.1440

C. Ahowesso, Approche expérimentale de la personnalisation de la chronothérapeutique par irinotecan, 2011.

I. Chau and D. Cunningham, Treatment in advanced colorectal cancer: what, when and how?, British Journal of Cancer, vol.110, issue.11, pp.1704-1723, 2009.
DOI : 10.1038/sj.bjc.6605061

S. Ohdo, T. Makinosumi, T. Ishizaki, E. Yukawa, and S. Higuchi, Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice, J Pharmacol Exp Ther, vol.283, pp.1383-1391, 1997.

T. Granda, D. Attino, R. Filipski, E. Vrignaud, P. Garufi et al., Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma, British Journal of Cancer, vol.398, issue.6, pp.999-1005, 2002.
DOI : 10.1038/sj.bjc.6600168

C. Garufi, B. Vanni, A. Aschelter, A. Zappala, and E. Bria, Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients, European Journal of Cancer, vol.42, issue.5, pp.608-624, 2006.
DOI : 10.1016/j.ejca.2005.03.012

D. Gholam, S. Giacchetti, C. Brezault-bonnet, M. Bouchahda, and D. Hauteville, Chronomodulated Irinotecan, Oxaliplatin, and Leucovorin-Modulated 5-Fluorouracil as Ambulatory Salvage Therapy in Patients with Irinotecan- and Oxaliplatin-Resistant Metastatic Colorectal Cancer, The Oncologist, vol.11, issue.10, pp.1072-80, 2006.
DOI : 10.1634/theoncologist.11-10-1072

F. Levi, A. Okyar, S. Dulong, P. Innominato, and J. Clairambault, Circadian Timing in Cancer Treatments, Annual Review of Pharmacology and Toxicology, vol.50, issue.1, pp.377-421, 2010.
DOI : 10.1146/annurev.pharmtox.48.113006.094626
URL : https://hal.archives-ouvertes.fr/hal-00780807

F. Levi and U. Schibler, Circadian Rhythms: Mechanisms and Therapeutic Implications, Annual Review of Pharmacology and Toxicology, vol.47, issue.1, pp.593-628, 2007.
DOI : 10.1146/annurev.pharmtox.47.120505.105208

D. Welsh, S. Yoo, A. Liu, J. Takahashi, and S. Kay, Bioluminescence Imaging of Individual Fibroblasts Reveals Persistent, Independently Phased Circadian Rhythms of Clock Gene Expression, Current Biology, vol.14, issue.24, pp.2289-95, 2004.
DOI : 10.1016/j.cub.2004.11.057

A. Carr and D. Whitmore, Imaging of single light-responsive clock cells reveals fluctuating free-running periods, Nature Cell Biology, vol.7, issue.3, pp.319-340, 2005.
DOI : 10.1016/S0960-9822(04)00029-6

A. Balsalobre, F. Damiola, and U. Schibler, A Serum Shock Induces Circadian Gene Expression in Mammalian Tissue Culture Cells, Cell, vol.93, issue.6, pp.929-966, 1998.
DOI : 10.1016/S0092-8674(00)81199-X

M. Izumo, T. Sato, M. Straume, and C. Johnson, Quantitative Analyses of Circadian Gene Expression in Mammalian Cell Cultures, PLoS Computational Biology, vol.13, issue.10, p.136, 2006.
DOI : 10.1371/journal.pcbi.0020136.sd001

S. Brown, G. Zumbrunn, F. Fleury-olela, N. Preitner, and U. Schibler, Rhythms of Mammalian Body Temperature Can Sustain Peripheral Circadian Clocks, Current Biology, vol.12, issue.18, pp.1574-83, 2002.
DOI : 10.1016/S0960-9822(02)01145-4

L. Pardini, B. Kaeffer, A. Trubuil, A. Bourreille, and J. Galmiche, Human Intestinal Circadian Clock: Expression of Clock Genes in Colonocytes Lining the Crypt, Chronobiology International, vol.20, issue.1, pp.951-61, 2005.
DOI : 10.1081/CBI-120030045

R. Mathijssen, R. Van-alphen, J. Verweij, W. Loos, and K. Nooter, Clinical pharmacokinetics and metabolism of irinotecan (CPT11), Clin Cancer Res, vol.7, pp.2182-94, 2001.

L. Rivory and R. J. , Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives, Pharmacology & Therapeutics, vol.68, issue.2, pp.269-96, 1995.
DOI : 10.1016/0163-7258(95)02009-8

N. Hanioka, S. Ozawa, H. Jinno, M. Ando, Y. Saito et al., Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin, Xenobiotica, vol.31, issue.10, pp.687-99, 2001.
DOI : 10.1080/00498250110057341

M. Tallman, J. Ritter, and P. Smith, DIFFERENTIAL RATES OF GLUCURONIDATION FOR 7-ETHYL-10-HYDROXY-CAMPTOTHECIN (SN-38) LACTONE AND CARBOXYLATE IN HUMAN AND RAT MICROSOMES AND RECOMBINANT UDP-GLUCURONOSYLTRANSFERASE ISOFORMS, Drug Metabolism and Disposition, vol.33, issue.7, pp.977-83, 2005.
DOI : 10.1124/dmd.104.003491

K. Kobayashi, B. Bouscarel, Y. Matsuzaki, S. Ceryak, and S. Kudoh, pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells, International Journal of Cancer, vol.56, issue.4, pp.491-497, 1999.
DOI : 10.1002/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M

T. Itoh, S. Itagaki, Y. Sumi, T. Hirano, and I. Takemoto, Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2, Cancer Chemotherapy and Pharmacology, vol.431, issue.5, pp.420-424, 2005.
DOI : 10.1007/s00280-004-0937-4

N. Smith, W. Figg, and A. Sparreboom, Pharmacogenetics of irinotecan metabolism and transport: An update, Toxicology in Vitro, vol.20, issue.2, pp.163-75, 2006.
DOI : 10.1016/j.tiv.2005.06.045

A. Lalloo, F. Luo, A. Guo, P. Paranjpe, and S. Lee, Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2), BMC Medicine, vol.20, issue.Suppl, p.16, 2004.
DOI : 10.1023/A:1026183200740

Y. Pommier, Topoisomerase I inhibitors: camptothecins and beyond, Nature Reviews Cancer, vol.24, issue.10, pp.789-802, 2006.
DOI : 10.1038/nrc1977

O. Sordet, Q. Khan, K. Kohn, and Y. Pommier, Apoptosis Induced by Topoisomerase Inhibitors, Current Medicinal Chemistry-Anti-Cancer Agents, vol.3, issue.4, pp.271-90, 2003.
DOI : 10.2174/1568011033482378

F. Goldwasser, I. Bae, M. Valenti, K. Torres, and Y. Pommier, Topoisomerase Irelated parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen, Cancer Res, vol.55, pp.2116-2137, 1995.

D. Subramanian, E. Kraut, A. Staubus, D. Young, and M. Muller, Analysis of topoisomerase I/DNA complexes in patients administered topotecan, Cancer Res, vol.55, pp.2097-103, 1995.

Y. Kuramoto, K. Hata, S. Koyanagi, S. Ohdo, and H. Shimeno, Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones, Biochemical Pharmacology, vol.71, issue.8, pp.1155-61, 2006.
DOI : 10.1016/j.bcp.2005.12.034

A. Okyar, E. Piccolo, C. Ahowesso, E. Filipski, and . Hossard, Strain- and Sex-Dependent Circadian Changes in Abcc2 Transporter Expression: Implications for Irinotecan Chronotolerance in Mouse Ileum, PLoS ONE, vol.36, issue.6884, p.20393, 2011.
DOI : 10.1371/journal.pone.0020393.g005

H. Ando, H. Yanagihara, K. Sugimoto, Y. Hayashi, and S. Tsuruoka, Daily Rhythms of P???glycoprotein Expression in Mice, Chronobiology International, vol.12, issue.4, pp.655-65, 2005.
DOI : 10.1081/CBI-120030045

J. Bassingthwaighte and C. Goresky, Modeling in the analysis of solute and water exchange in the microvasculature, HandBook of Physiology, pp.560-570, 1984.

L. Tabas and A. Dantzig, A high-throughput assay for measurement of multidrug resistance protein-mediated transport of leukotriene C4 into membrane vesicles, Analytical Biochemistry, vol.310, issue.1, pp.61-67, 2002.
DOI : 10.1016/S0003-2697(02)00282-8

B. Woebking, G. Reuter, R. Shilling, S. Velamakanni, and S. Shahi, Drug-Lipid A Interactions on the Escherichia coli ABC Transporter MsbA, Journal of Bacteriology, vol.187, issue.18, pp.6363-6372, 2005.
DOI : 10.1128/JB.187.18.6363-6369.2005

X. Yang, Z. Hu, A. Xu, W. Duan, and Y. Zhu, A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-?? Inhibitor, Journal of Pharmacology and Experimental Therapeutics, vol.319, issue.1, pp.82-104, 2006.
DOI : 10.1124/jpet.106.103606

L. Rivory, M. Bowles, R. J. Pond, and S. , Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase, Biochemical Pharmacology, vol.52, issue.7, pp.1103-1114, 1996.
DOI : 10.1016/0006-2952(96)00457-1

P. Tobin, S. Clarke, J. Seale, S. Lee, and M. Solomon, The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours, British Journal of Clinical Pharmacology, vol.57, issue.1, pp.122-131, 2006.
DOI : 10.1016/0006-2952(93)90636-B

J. Gagné, V. Montminy, P. Belanger, K. Journault, and G. Gaucher, Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-hydroxycamptothecin (SN-38), Molecular Pharmacology, vol.62, issue.3, pp.608-625, 2002.
DOI : 10.1124/mol.62.3.608

N. Hansen, The CMA evolution strategy: a comparing review. Towards a new evolutionary computation Advances on estimation of distribution algorithms, pp.75-102, 2006.

F. Levi, A. Altinok, J. Clairambault, and A. Goldbeter, Implications of circadian clocks for the rhythmic delivery of cancer therapeutics, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol.22, issue.4, pp.3575-98, 2008.
DOI : 10.1080/07420520500179969

C. Basdevant, J. Clairambault, and F. Levi, Optimisation of time-scheduled regimen for anti-cancer drug infusion, ESAIM: Mathematical Modelling and Numerical Analysis, vol.39, issue.6, pp.1069-1086, 2005.
DOI : 10.1051/m2an:2005052

C. Henrich, H. Bokesch, M. Dean, S. Bates, and R. Robey, A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity, Journal of Biomolecular Screening, vol.53, issue.2, pp.176-83, 2006.
DOI : 10.1101/gr.GR-1649R

R. Hayeshi, C. Hilgendorf, P. Artursson, P. Augustijns, and B. Brodin, Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories, European Journal of Pharmaceutical Sciences, vol.35, issue.5, pp.383-96, 2008.
DOI : 10.1016/j.ejps.2008.08.004

G. Lemma, Z. Wang, M. Hamman, N. Zaheer, and J. Gorski, The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates, Clinical Pharmacology & Therapeutics, vol.79, issue.3, pp.218-248, 2006.
DOI : 10.1016/j.clpt.2005.11.001

S. Reischl and A. Kramer, Kinases and phosphatases in the mammalian circadian clock, FEBS Letters, vol.34, issue.10, pp.1393-1402, 2011.
DOI : 10.1016/j.febslet.2011.02.038

B. Porsin, J. Formento, E. Filipski, M. Etienne, and M. Francoual, Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver, European Journal of Cancer, vol.39, issue.6, pp.822-830, 2003.
DOI : 10.1016/S0959-8049(02)00598-1

Y. Pommier, J. Barcelo, V. Rao, O. Sordet, and A. Jobson, Repair of Topoisomerase I???Mediated DNA Damage, Prog Nucleic Acid Res Mol Biol, vol.81, pp.179-229, 2006.
DOI : 10.1016/S0079-6603(06)81005-6

A. Sancar, L. Lindsey-boltz, T. Kang, J. Reardon, and J. Lee, Circadian clock control of the cellular response to DNA damage, FEBS Letters, vol.15, issue.12, pp.2618-2643, 2010.
DOI : 10.1016/j.febslet.2010.03.017

G. Bjarnason and R. Jordan, Rhythms in Human Gastrointestinal Mucosa and Skin, Chronobiology International, vol.53, issue.1, pp.129-169, 2002.
DOI : 10.1093/jnci/86.21.1608

T. Granda, X. Liu, R. Smaaland, N. Cermakian, and E. Filipski, Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor, The FASEB Journal, vol.19, pp.304-310, 2005.
DOI : 10.1096/fj.04-2665fje
URL : https://hal.archives-ouvertes.fr/hal-00187546

D. Maria, E. Fages, F. Soliman, and S. , On Coupling Models Using Model-Checking: Effects of Irinotecan Injections on the Mammalian Cell Cycle, Lecture Notes in Computer Science, vol.62, issue.3, pp.142-157, 2009.
DOI : 10.1007/978-3-540-88562-7_19

S. Guichard, C. Terret, I. Hennebelle, I. Lochon, and P. Chevreau, CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues, British Journal of Cancer, vol.80, issue.3-4, pp.364-70, 1999.
DOI : 10.1038/sj.bjc.6690364

K. May, V. Minarikova, K. Linnemann, M. Zygmunt, and H. Kroemer, Role of the Multidrug Transporter Proteins ABCB1 and ABCC2 in the Diaplacental Transport of Talinolol in the Term Human Placenta, Drug Metabolism and Disposition, vol.36, issue.4, pp.740-744, 2008.
DOI : 10.1124/dmd.107.019448

P. Chomczynski and N. Sacchi, The single-step method of RNA isolation by acid guanidinium thiocyanate???phenol???chloroform extraction: twenty-something years on, Nature Protocols, vol.22, issue.2, pp.581-586, 2006.
DOI : 10.1006/abio.1987.9999

K. Akimoto, A. Kawai, and K. Ohya, Kinetic Studies of the Hydrolysis and Lactonization of Camptothecin and Its Derivatives, CPT-11 and SN-38, in Aqueous Solution., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.42, issue.10, pp.2135-2138, 1994.
DOI : 10.1248/cpb.42.2135

L. Rivory and R. J. , Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma, Journal of Chromatography B: Biomedical Sciences and Applications, vol.661, issue.1, pp.133-174, 1994.
DOI : 10.1016/0378-4347(94)00340-8

V. Pavillard, C. Agostini, S. Richard, V. Charasson, and D. Montaudon, Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines, Cancer Chemotherapy and Pharmacology, vol.49, issue.4, pp.329-364, 2002.
DOI : 10.1007/s00280-001-0416-0